 Secukinumab, a monoclonal antibody that neutralizes interleukin-17a, was found to have higher responder rates than etinoset and ustikinumab in patients with moderate to severe plaque psoriasis. Factors associated with response included lower prevalence of previous systemic or biologic treatment, metabolic syndrome, hypertension, diabetes, and current smoking. Early onset of response, bosy 50 at week 4 or 8, correlated with sustained efficacy at week 16. This article was authored by Andreas Pinter, Sacha Girdes, Karis Papavassilis, and others.